ArticleFrontiers in big data2024
Enhancing cancer stage prediction through hybrid deep neural networks: a comparative study.
Article in Frontiers in big data, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A novel statistical feature selection framework for biomarker discovery and cancer classification via multiomics integration.BMC medical research methodology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efficiently detecting and treating cancer at an early stage is crucial to improve the overall treatment process and mitigate the risk of disease progression. In the realm of research, the utilization of artificial intelligence technologies holds significant promise for enhancing advanced cancer diagnosis. Nonetheless, a notable hurdle arises when striving for precise cancer-stage diagnoses through the analysis of gene sets. Issues such as limited sample volumes, data dispersion, overfitting, and the use of linear classifiers with simple parameters hinder prediction performance. This study introduces an innovative approach for predicting early and late-stage cancers by integrating hybrid deep neural networks. A deep neural network classifier, developed using the open-source TensorFlow library and Keras network, incorporates a novel method that combines genetic algorithms, Extreme Learning Machines (ELM), and Deep Belief Networks (DBN). Specifically, two evolutionary techniques, DBN-ELM-BP and DBN-ELM-ELM, are proposed and evaluated using data from The Cancer Genome Atlas (TCGA), encompassing mRNA expression, miRNA levels, DNA methylation, and clinical information. The models demonstrate outstanding prediction accuracy (89.35%-98.75%) in distinguishing between early- and late-stage cancers. Comparative analysis against existing methods in the literature using the same cancer dataset reveals the superiority of the proposed hybrid method, highlighting its enhanced accuracy in cancer stage prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.